TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27645620
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Study: 27645620
Drug: Mega dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mega dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Study: 22799111
Drug: Glimepiride 1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1/2 mg
Study: 18266669
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 5 microg/min
Study: 18266669
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 10 microg/min
Study: 18266669
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 15 microg/min
Study: 18266669
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion at 20 microg/min
Study: 15715892
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice a day for 2 months
Study: 11302252
Drug: BCNU 150
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU 150 mg/m2/i.v. followed by temozolomide 550 mg/m2/p.o. (Arm A)
Study: 11302252
Drug: BCNU 100
Normalized name: BCNU 100 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU 100 mg/m2/i.v. followed by temozolomide 400 mg/m2/p.o. (Arm B)
Study: 11302252
Drug: Temozolomide pharmacokinetics
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide pharmacokinetics
Study: 8135447
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (100 mg of recombinant tissue plasminogen activator)
Study: 2811366
Drug: Aminoglutethimide treatment
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide treatment (250 mg q.i.d. with hydrocortisone 50 mg b.i.d. for 2 weeks, then 25 mg b.i.d.)
Study: 23618477
Drug: L-carnosine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnosine (1500 mg)
Study: 20691839
Drug: Primary PCI
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary PCI with adjunctive enoxaparin and abciximab
Study: 18257780
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg before each main meal)
Study: 9376455
Drug: Drug-free (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free (after haloperidol)
Study: 1587076
Drug: Stopping medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping medication under open-label conditions (weeks 190 to 210)
Study: 1587076
Drug: Transfer from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer from fenfluramine plus phentermine to no medication
Study: 26072017
Drug: M72/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01E vaccine
Study: 24607029
Drug: CRT-D treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D treatment
Study: 24607029
Drug: CRT-D treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D treatment with left bundle branch block (LBBB)
Study: 17631314
Drug: Aripiprazole 20
Normalized name: aripiprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 20 mg/day
Study: 6342332
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg X 3 daily
Study: 18628266
Drug: Topical conjunctival
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical conjunctival anaesthesia with a 1:1 mixture of lidocaine 2% and levobupivacaine 0.75%
Study: 1963015
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg/day (4000 anti-Factor Xa IU), administered in one or two subcutaneous injections
Study: 1963015
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg/day (one or two injections daily)
Study: 1963015
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg/day, begun 12 h pre-operatively
Study: 380804
Drug: Levamisole, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole, 150 mg/day orally for 3 consecutive days every other week
Study: 29735587
Drug: Low-dose pitavastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pitavastatin (1 mg/d)
Study: 28570161
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily (n=9)
Study: 23561330
Drug: Low-dose β‐conglycinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose β‐conglycinin (2.3 g/d)
Study: 23561330
Drug: High-dose β‐conglycinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose β‐conglycinin (4.6 g/d)
Study: 23561330
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four casein tablets/d)
Study: 22717090
Drug: Risperidone with
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone with light therapy
Study: 18235414
Drug: Anti-angiogenesis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenesis treatment (humanized monoclonal antibody targeting vascular endothelial growth factor)
Study: 18235414
Drug: Anti-angiogenesis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenesis treatment (low-molecular-weight anti tyrosine kinases)
Study: 11136285
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid alone (10 mg.day/kg)
Study: 11136285
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (chenodeoxycholic acid plus ursodeoxycholic acid, 5 mg.day/kg each)
Study: 9700583
Drug: Clodronate 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1,600 mg/day for one year
Study: 7850850
Drug: 3 quick
Normalized name: Celebrate Vitamin D3 Quick-Melt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 quick rinses with 10 ml of water (experiment A)
Study: 7850850
Drug: 1 long-lasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 long-lasting rinse with 5 ml of water (experiment B)
Study: 7850850
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of toothpaste slurry with 100 ml of de-ionized water (experiment D)
Study: 3139730
Drug: Astemizole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole, 10 mg/day
Study: 27236732
Drug: Curative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative treatment (surgery, radiosurgery, or embolization)
Study: 23544333
Drug: Flurbiprofen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (1 mg x kg(‐1), 50 mg max) administered before surgery in group F (n = 11)
Study: 23544333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C, n = 13) with no flurbiprofen administration
Study: 20723545
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESAs) for patients with early-onset anemia (≤ 8 weeks of treatment)
Study: 20723545
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESAs) for patients with late-stage anemia
Study: 20723545
Drug: Magnitude of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnitude of Hb decrease (>3 g/dL)
Study: 20723545
Drug: Magnitude of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnitude of Hb decrease (≤3 g/dL)
Study: 12720050
Drug: Menaquinone 4
Normalized name: menaquinone 45 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone 4 (MK(4)) at a dose of 45 mg/day for 2 weeks
Study: 8912486
Drug: Rizatriptan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (20 mg)
Study: 8912486
Drug: Rizatriptan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (40 mg)
Study: 4047702
Drug: Aspirin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1 g)
Study: 6351216
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Dipyridamole (ASA + D)
Study: 6351216
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Dipyridamole (AD)
Study: 6351216
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) and Aspirin + Dipyridamole (AD)
Study: 27100375
Drug: Composite intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite intervention including a personalized weight graph, education on recommended weight gain, prescription of exercise, and monitoring of weight until 1 year after delivery
Study: 27100375
Drug: Gestational weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestational weight gain above Institute of Medicine recommendations
Study: 22275142
Drug: Esreboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esreboxetine 4 mg/day
Study: 22275142
Drug: Esreboxetine 8
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esreboxetine 8 mg/day
Study: 22275142
Drug: Esreboxetine 10
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esreboxetine 10 mg/day
Study: 20619634
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy with sequential chemotherapy
Study: 18156031
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus interferon alfa-2a (10 mg/kg every 2 weeks; 9 MIU subcutaneously three times weekly)
Study: 18156031
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus interferon alfa-2a (9 MIU subcutaneously three times weekly)
Study: 15153904
Drug: Inactive vehicle
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive vehicle applied twice daily
Study: 15153904
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing with tacrolimus 2.5% in ethanol
Study: 9519948
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 microg twice daily for 6 months
Study: 7595697
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HD-CNV) with cyclophosphamide 2.4 g/m2, mitoxantrone 35 to 45 mg/m2, and etoposide (VP16) 2.5 g/m2
Study: 7595697
Drug: Conventional-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose chemotherapy (CNV) with cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1.4 mg/m2
Study: 23593156
Drug: New occlusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New occlusal adjustment therapy
Study: 19229275
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (topical antibiotic for 10 days and topical corticosteroid for 1 month)
Study: 18709032
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg epidural butorphanol with bupivacaine
Study: 18709032
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg epidural butorphanol with bupivacaine
Study: 15341548
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise and coping classes (6 months, 3 meetings weekly, 45 minutes each for exercise and 2 meetings weekly, 45 minutes each for coping)
Study: 15341548
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education control intervention (6 months, 1 meeting weekly, 45 minutes)
Study: 7569150
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined therapy (CCT) with 2 mg estradiol valerate and 2.5 mg medroxyprogesterone acetate
Study: 2804252
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release theophylline tablets
Study: 31900673
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including various preparation designs)
Study: 31900673
Drug: Thin veneers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin veneers and preparations with medium to high dentin portions
Study: 26198394
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine content cigarettes (VLNC) at 0.5 mg/cigarette for 7 months followed by 12 months with no intervention
Study: 23538479
Drug: Antiplatelet or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet or anticoagulant therapy
Study: 23538479
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet or anticoagulant therapy
Study: 20226548
Drug: Argatroban (ARG250:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (ARG250: 250 μg/kg bolus, 15 μg/kg/min infusion)
Study: 20226548
Drug: Argatroban (ARG300:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (ARG300: 300 μg/kg bolus, 20 μg/kg/min infusion)
Study: 20226548
Drug: Argatroban (ARG350:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (ARG350: 350 μg/kg bolus, 25 μg/kg/min infusion)
Study: 20226548
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH: 70-100 IU/kg bolus)
Study: 20226548
Drug: Argatroban (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (all doses)
Study: 19692798
Drug: GW406381 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 70 mg
Study: 19692798
Drug: GW406381 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 10 mg
Study: 9425968
Drug: Propofol (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2-4 mg/kg/h)
Study: 3307727
Drug: Buprenorphine by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine by intermittent intravenous injection
Study: 3307727
Drug: Morphine by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine by continuous intravenous infusion
Study: 16548084
Drug: NMES therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMES therapy
Study: 27260592
Drug: Articulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulation therapy (40 intensive sessions over 10 weeks)
Study: 25002136
Drug: Phosphorus (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus (500 mg)
Study: 21087898
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg daily for 5 years)
Study: 18281670
Drug: physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: physician's choice (PC) of treatment (dacarbazine, temozolomide, interleukin-2, or complete tumor resection)
Study: 9215817
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) 250 mg four times daily with hydrocortisone (HC) 40 mg daily
Study: 9215817
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MA plus AG at the same dosages
Study: 2447997
Drug: goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: goserelin 3.6 mg depot (Zoladex)
Study: 2447997
Drug: stilboestrol 3
Normalized name: Stilboestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: stilboestrol 3 mg/day
Study: 30145929
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of tafamidis
Study: 30145929
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tafamidis
Study: 27318021
Drug: Vardenafil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil administered via inhalation using an ultrasonic nebulizer
Study: 27318021
Drug: Vardenafil 10-mg
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10-mg oral tablet
Study: 22891807
Drug: Interactive version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interactive version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Study: 22891807
Drug: Didactic version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didactic version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Study: 11240954
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus (FK506)
Study: 9248782
Drug: Amoxycillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1 g, Clamoxyl dispersible tablet)
Study: 31409749
Drug: Ropinirole eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole eye drops (3.75 mg/m2)
Study: 28678855
Drug: Oral presentations
Normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral presentations
Study: 21232119
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12 (1000 μg daily, N = 26)
Study: 12562865
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (4 g/d of ethyl esters of EPA and DHA)
Study: 7886548
Drug: Exchange transfusion
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exchange transfusion therapy (10-15 units of blood)
Study: 22278200
Drug: Exchange transfusion
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exchange transfusion therapy
Study: 24637568
Drug: ω-3 fatty-acid
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 fatty-acid consumption (MorDHA capsules: 435 mg of docosahexaenoic acid and 65 mg of eicosapentaenoic acid) for 14 months
Study: 24637568
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 14 months
Study: 16254727
Drug: Levofloxacin 600
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 600 mg/day for 1 day
Study: 16254727
Drug: Levofloxacin 300
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 300 mg/day for 3 days
Study: 16254727
Drug: Levofloxacin 600
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 600 mg for 1 day
Study: 10348224
Drug: Atovaquone/proguanil (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone/proguanil (1,000 mg and 400 mg, orally at 24-hr intervals for three doses)
Study: 6293718
Drug: Cefotaxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime administered 30 to 90 minutes preoperatively, every 60 to 90 minutes during surgery, and immediately postoperatively.
Study: 6293718
Drug: Cefotaxime or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime or cefazolin administered according to the same regimen as the first group, plus every eight hours for 24 hours postoperatively.
Study: 31831051
Drug: YH0618 granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH0618 granule (6 g twice a day, 6 days a week, mixed with 300 ml warm water from the first to the fourth chemotherapy cycle)
Study: 31831051
Drug: Placebo granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granule (same dosage and administration as YH0618)
Study: 25335642
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SPT + MAD
Study: 17223805
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 mg.kg‐1 combined with suxamethonium 1 mg.kg‐1 (group S)
Study: 17223805
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 mg.kg‐1 combined with remifentanil 1.25 microg.kg‐1 (group R)
Study: 15189395
Drug: Montelukast, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, a leukotriene receptor antagonist, used in real-world management of asthma
Study: 7881965
Drug: Primary systemic
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary systemic therapy
Study: 9744711
Drug: Clinical evaluation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical evaluation of response to treatment
Study: 10456621
Drug: Abrupt withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt withdrawal of warfarin (group A)
Study: 7831656
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal of warfarin (group B)
Study: 3149240
Drug: Flumazenil 1
Normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 1 mg i.v.
Study: 29630032
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 4 mg (1 mL) with 30 mL ropivacaine 0.375%
Study: 29630032
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 10 mg (2.5 mL) with 30 mL ropivacaine 0.375%